Skip to search formSkip to main contentSkip to account menu

CC-4047

Known as: CC 4047, CC4047 
National Institutes of Health

Related topics

Related topics

2 relations

Broader (2)

actimidpomalidomide

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2011
2011
Efficacy of pomalidomide plus low-dose dexamethasone in multiple myeloma patients despite previous use of lenalidomide.
8067 Background: Pomalidomide (CC4047 or Pom) is the newest oral immunomodulatory agent. It yields less neuropathy than… 
2011
2011
A phase I, dose-escalation study of pomalidomide (CC-4047) in combination with gemcitabine in metastatic pancreas cancer.
2010
2010
Phase 2 Study of 2 Modalities of Pomalidomide (CC4047) Plus Low-Dose Dexamethasone as Therapy for Relapsed Multiple Myeloma. IFM 2009-02
Abstract 859 Method: This study was addressed to patients with MM who were symptomatic and progressive following at least two… 
2010
2010
Activity of pomalidomide plus dexamethasone (Pom/dex) in dual lenalidomide/bortezomib refractory multiple myeloma (MM).
8002 Background: Patients with MM who have progressed after multiple novel agents have limited treatment options. Pomalidomide… 
2008
2008
Pomalidomide (CC4047) Plus Low-Dose Dexamethasone (Pom/dex) Is Highly Effective Therapy in Relapsed Multiple Myeloma
Background: Thalidomide and its analogue lenalidomide have high response rates among patients with newly diagnosed as well as… 
2006
2006
The Thalidomide Analogue, CC-4047, Induces Apoptosis Signaling and Growth Arrest in Childhood Acute Lymphoblastic Leukemia Cells In vitro and In vivo
Purpose: Thalidomide and its analogues have shown promise in the treatment of multiple myeloma but their therapeutic potential… 
2006
2006
Lenalidomide (Revlimid®, CC-5013) and Actimid™ (CC-4047) inhibit the function and expansion of T regulatory (Treg) cells in vitro: Implications for anti-tumor activity in vivo
Proc Amer Assoc Cancer Res, Volume 47, 2006 4882 Lenalidomide and CC-4047 are second generation IMiDs® having immunomodulatory… 
Review
2006
Review
2006
Therapeutic use of immunomodulatory drugs in the treatment of multiple myeloma
Immunomodulatory drugs, such as thalidomide, lenalidomide (Revlimid®, CC-5013) and actimid (CC-4047), have a broad spectrum of… 
2005
2005
Markers of endothelial and haemostatic function in the treatment of relapsed myeloma with the immunomodulatory agent ActimidTM (CC‐4047) and their relationship with venous thrombosis
Abstract:  We evaluated the serum/plasma levels of cytokines [interleukin (IL)‐6, vascular endothelial growth factor (VEGF… 
2004
2004
Phase II study of CC-4047 in patients with metastatic hormone-refractory prostate cancer (HRPCa).
4701 Background: Thalidomide is a potentially effective therapy for patients with metastatic HRPC. CC-4047 is a thalidomide… 
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)